Stem cell is a cell with the ability to self-renew over a long time and multilineage differentiation to give rise to specialized cells, such as muscle cells, blood cells, and brain cells.
We believe we are entering a new era of cell therapy. The ability to use healthy cells as medicines provides new tools to meaningfully change the outcome of many human diseases.
Health-Biotech JISHI (H&B JISHI) is developing off-the-shelf innovative cellular medicines for the treatment of a broad range of severe and life-threatening diseases.

The H&B JISHI’s portfolio of phase II/III product candidates comprises UC-MSC for steroid-refractory acute graft versus host disease (acute GVHD), for the treatment of moderate to severe acute-on-chronic liver failure (ACLF). The phase I/II product candidates include UC-MSC for refractory immune thrombocytopenia (ITP), spinal cord injury (SCI), stroke, as well as acute respiratory distress syndrome (ARDS). P-MSC hydrogel for diabetic foot ulcer and radiation skin injury. CD106+MSC for critical limb ischemia.

Investors.